News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Anthropic priced its IPO at $83 per Class A share.
  • The Anthropic offering totals 980,000,000 shares, mostly sold by the company.
  • Anthropic will list on Nasdaq under ticker ANT on Nov 19, 2026, with closing expected Nov 20.
  • Tilly's has about $52 million net cash and trades near 7.6x EV/EBITDA.
  • Analyst projects TLYS could reach $6 within 180 trading days citing margin improvements.

Latest Articles

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

Dyne Therapeutics announces FDA clearance of its Investigational New Drug application for DYNE-302, advancing its third clinical program leveraging the FORCE platform to treat facioscapulohumeral muscular dystrophy (FSHD), a rare progressive neuromuscular disorder with no approved therapies. The Phase 1 trial will assess safety, tolerability, pharm…

Riot Announces Second Quarter 2026 Earnings Conference Call

Riot Announces Second Quarter 2026 Earnings Conference Call

Riot Platforms, Inc., a leader in large-scale data centers and bitcoin mining, announced its Q2 2026 earnings call set for August 5, 2026. The company focuses on developing digital infrastructure and mining operations across Texas and Kentucky, with engineering facilities in Denver and Houston. The press release reiterates forward-looking statement…

Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth

Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth

Nasus Pharma, a clinical-stage biopharmaceutical company developing innovative intranasal therapies, announced the appointment of pharmaceutical industry veteran Brendan P. O'Grady as CEO. O'Grady will lead the next phase of growth with an emphasis on unlocking the commercial potential of NS002, an intranasal epinephrine treatment targeting a $2 bi…

PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufacturing Agreement Through A&B Aerospace Inc.

PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufacturing Agreement Through A&B Aerospace Inc.

PMGC Holdings Inc., through its subsidiary A&B Aerospace, has entered a long-term manufacturing agreement with Precision Aerospace & Defense Group to supply precision-machined aerospace and defense components. Additionally, PMGC made a $500,000 strategic equity investment in PAD Group, further aligning their partnership. This collaboration position…

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals reported robust second quarter 2026 financial results highlighted by 55% year-over-year net product revenue growth for ARCALYST®, reaching $243.6 million in Q2. The company raised its full-year 2026 ARCALYST revenue guidance to $980-$995 million. Clinical progress continues with promising Phase 2 data for KPL-387 supporting …

DCX’s DexTrader Announces Upgrade, Targeting On-Chain Yield-Bearing Collateralized Derivatives Data Services Segment

DCX’s DexTrader Announces Upgrade, Targeting On-Chain Yield-Bearing Collateralized Derivatives Data Services Segment

Digital Currency X Technology Inc. has announced comprehensive upgrades to its DexTrader on-chain data platform, enhancing data architecture, omnichain capabilities, and user services. The company aims to target the digital asset information niche for token-based derivatives, yield instruments, and collateralized assets, positioning DexTrader as a …

PayPal reiterates turnaround amid takeover debate after a pivotal quarter

PayPal reiterates turnaround amid takeover debate after a pivotal quarter

PayPal pushed forward with an aggressive turnaround program after reporting a quarter that outperformed expectations, increasing its 2026 profit projection and detailing multi-year cost, organizational and technology initiatives. The moves come as the company faces a $60.50-per-share takeover bid that its board has deemed insufficient and as compet…

Lifecore Biomedical Signs Three New Customer Agreements

Lifecore Biomedical Signs Three New Customer Agreements

Lifecore Biomedical announced three new customer agreements, including a late-stage regenerative medicine program and two early-stage projects supporting medical technology development. These agreements diversify Lifecore's pipeline and are expected to contribute to revenue starting in 2028, reinforcing its position as a key player in the CDMO mark…

AZZ: Secular Demand and Lower Leverage Make a Convincing Long Setup

AZZ: Secular Demand and Lower Leverage Make a Convincing Long Setup

AZZ Inc. combines structural demand for corrosion protection and power transmission with a cleaner balance sheet and improving margins. Management's FY27 guidance (sales $1.73-$1.78B, adj. EBITDA up to $400M, adj. EPS up to $7.00) plus steady free cash flow ($169M last reported) supports upside from the current price. Trade idea: enter $149.00, sto…

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

Cullinan Therapeutics announced a positive End-of-Phase 1 meeting with the FDA regarding their novel T cell engager CLN-049 for acute myeloid leukemia (AML). The FDA's feedback supports initiating a potentially registrational Phase 2 study in relapsed/refractory AML patients in Q3 2026. CLN-049 targets FLT3-expressing leukemia cells and has receive…

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

Atea Pharmaceuticals announced that its oral antiviral combination Bemnifosbuvir/Ruzasvir (BEM/RZR) achieved statistical non-inferiority to the standard treatment Sofosbuvir/Velpatasvir (SOF/VEL) in the Phase 3 C-BEYOND trial for treating chronic Hepatitis C Virus (HCV) infection. The 8-week BEM/RZR regimen demonstrated high cure rates across patie…

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company specializing in cancer therapies, announced its plan to release its second quarter 2026 financial results on August 4, 2026, followed by a conference call and webcast. The company highlighted its FDA-approved products Revuforj® and Niktimvo™ and ongoing clinical trials as part of …

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Altimmune, Inc. announced positive topline results from its RECLAIM Phase 2 trial of pemvidutide, a dual glucagon/GLP-1 receptor agonist, in patients with moderate to severe alcohol use disorder. The trial met its primary endpoint with a statistically significant reduction in heavy drinking days and achieved key secondary endpoints recognized by th…

Factorial Sets Date for Second Quarter 2026 Results

Factorial Sets Date for Second Quarter 2026 Results

Factorial Energy Inc., a Nasdaq-listed solid-state battery technology leader, will release its second quarter 2026 financial results on August 11, 2026, followed by a webcast and conference call to discuss performance and updates. The company is known for its proprietary battery platforms and collaborations with major automotive manufacturers.